Oxcarbazepine (Epilepsy) updated on 04-22-2025

Microcephaly / Small head circumference for gestational age

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16081
R66735		 Christensen (Oxcarbazepine) (Epilepsy) (Controls exposed to LTG), 2024 Microcephaly (z-score for head circumference ≤3rd percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.16 [0.83;1.61] C
excluded (control group) 		48/1,462   151/5,299 199 1,462
ref
S16029
R66539		 Christensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 Microcephaly (z-score for head circumference ≤3rd percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 0.96 [0.66;1.39] 48/1,462   699/22,227 747 1,462
ref
Total 1 studies 0.96 [0.66;1.39] 747 1,462
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024Christensen, 2024 1 0.96[0.66; 1.39]7471,4620%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Epilepsy) (Controls unexposed, general population;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.96[0.66; 1.39]7471,462 -NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.96[0.66; 1.39]7471,462 -NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 1 Tags Adjustment   - Yes  - Yes 0.96[0.66; 1.39]7471,462 -NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 1 All studiesAll studies 0.96[0.66; 1.39]7471,462 -NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 16081

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.96[0.66; 1.39]7471,462 -NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.16[0.83; 1.61]1991,462 -NAChristensen (Oxcarbazepine) (Epilepsy) (Controls exposed to LTG), 2024 10.510.01.0